Fundamental significance of specific KRAS mutant types for prognosis of unresectable pancreatic cancer patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F16%3AN0000021" target="_blank" >RIV/26475821:_____/16:N0000021 - isvavai.cz</a>

Výsledek na webu

<a href="http://cancerres.aacrjournals.org/content/76/24_Supplement/A19" target="_blank" >http://cancerres.aacrjournals.org/content/76/24_Supplement/A19</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Fundamental significance of specific KRAS mutant types for prognosis of unresectable pancreatic cancer patients

Popis výsledku v původním jazyce

Abstract at AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; May 12-15, 2016; Orlando, FL; The overall survival prognosis of patients in advanced unresectable stages of pancreatic ductal adenocarcinoma is poor, typically ranging from days to months from diagnosis. A prognostic marker would be useful in management of the disease guiding rational decisions between systemic or palliative therapy ensuring longest survival at an adequate quality of life. Due to its frequent occurrence in PDAC, prognostic value of KRAS mutation status has traditionally been studied. The results, however, were often contradictory. In the present work, we explore the role of individual KRAS mutant types in the assessment of prognosis. In addition, we explore KRAS mutation analysis from circulating tumor DNA (ctDNA) as a source material to eliminate biopsy-associated burden to the patient. FNA-biopsy followed by cytology evaluation and molecular testing of KRAS is feasible in routine management of pancreatic cancer patients. Differentiation of specific KRAS mutation types (above all the crucial Gly12Asp) is imperative for assessment of prognosis in the rational therapy decision process.

Název v anglickém jazyce

Fundamental significance of specific KRAS mutant types for prognosis of unresectable pancreatic cancer patients

Popis výsledku anglicky

Abstract at AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; May 12-15, 2016; Orlando, FL; The overall survival prognosis of patients in advanced unresectable stages of pancreatic ductal adenocarcinoma is poor, typically ranging from days to months from diagnosis. A prognostic marker would be useful in management of the disease guiding rational decisions between systemic or palliative therapy ensuring longest survival at an adequate quality of life. Due to its frequent occurrence in PDAC, prognostic value of KRAS mutation status has traditionally been studied. The results, however, were often contradictory. In the present work, we explore the role of individual KRAS mutant types in the assessment of prognosis. In addition, we explore KRAS mutation analysis from circulating tumor DNA (ctDNA) as a source material to eliminate biopsy-associated burden to the patient. FNA-biopsy followed by cytology evaluation and molecular testing of KRAS is feasible in routine management of pancreatic cancer patients. Differentiation of specific KRAS mutation types (above all the crucial Gly12Asp) is imperative for assessment of prognosis in the rational therapy decision process.

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13638" target="_blank" >NT13638: Klinický význam vyšetření epigenetických faktorů pro zpřesnění diagnostiky, odhadu prognózy a rizika rekurence po kurativní resekci karcinomu pankreatu.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů